Intranasal anthrax vaccine - ProStrakan

Drug Profile

Intranasal anthrax vaccine - ProStrakan

Alternative Names: Intranasal anthrax

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Archimedes Pharma
  • Developer Kyowa Kirin International; Takeda
  • Class Anthrax vaccines; Bacterial vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Anthrax

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Anthrax in United Kingdom (Intranasal)
  • 05 Aug 2014 Archimedes Pharma has been acquired by ProStrakan
  • 05 Oct 2012 LigoCyte Pharmaceuticals has been acquired and merged into Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top